This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tian, F. Articles by Roberts, A. B. Search for Related Content PubMed PubMed Citation Articles by Tian, F. Articles by Roberts, A. B.

Smad-Binding Defective Mutant of Transforming Growth Factor ß Type I Receptor Enhances Tumorigenesis but Suppresses Metastasis of Breast Cancer Cell Lines

Laboratory of ¹ Cell Regulation and Carcinogenesis and ² Cellular and Molecular Biology, National Cancer Institute, Bethesda, Maryland, and ³ Department of Pathology, University of Washington, Seattle, Washington

The role of transforming growth factor ß (TGF-ß) in carcinogenesis is complex, with tumor suppressor and pro-oncogenic activities depending on the particular tumor cell and its stage in malignant progression. We previously have demonstrated in breast cancer cell lines that Smad2/3 signaling played a dominant role in mediating tumor suppressor effects on well-differentiated breast cancer cell lines grown as xenografts and prometastatic effects on a more invasive, metastatic cell line. Our present data based on selective interference with activation of endogenous Smad2 and Smad3 by stable expression of a mutant form of the TGF-ß type I receptor (RImL45) unable to bind Smad2/3 but with a functional kinase again show that reduction in Smad2/3 signaling by expression of RImL45 enhanced the malignancy of xenografted tumors of the well-differentiated MCF10A-derived tumor cell line MCF10CA1h, resulting in formation of larger tumors with a higher proliferative index and more malignant histologic features. In contrast, expression of RImL45 in the more aggressive MCF10CA1a cell line strongly suppressed formation of lung metastases following tail vein injection. These results suggest a causal, dominant role for the endogenous Smad2/3 signaling pathway in the tumor suppressor and prometastatic activities of TGF-ß in these cells. Using an in vitro assay, we further show that non-Smad signaling pathways, including p38 and c-Jun NH₂-terminal kinase, cooperate with TGF-ß/Smads in enhancing migration of metastatic MCF10CA1a cells, but that, although necessary for migration, these other pathways are not sufficient for metastasis.

This article has been cited by other articles:

				D. Melisi, S. Ishiyama, G. M. Sclabas, J. B. Fleming, Q. Xia, G. Tortora, J. L. Abbruzzese, and P. J. Chiao LY2109761, a novel transforming growth factor {beta} receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis Mol. Cancer Ther., April 1, 2008; 7(4): 829 - 840. [Abstract] [Full Text] [PDF]

				D. S. Rosman, S. Phukan, C.-C. Huang, and B. Pasche TGFBR1*6A Enhances the Migration and Invasion of MCF-7 Breast Cancer Cells through RhoA Activation Cancer Res., March 1, 2008; 68(5): 1319 - 1328. [Abstract] [Full Text] [PDF]

				H. J. You, M. W. Bruinsma, T. How, J. H. Ostrander, and G. C. Blobe The type III TGF- receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation Carcinogenesis, December 1, 2007; 28(12): 2491 - 2500. [Abstract] [Full Text] [PDF]

				B. C. Willis and Z. Borok TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease Am J Physiol Lung Cell Mol Physiol, September 1, 2007; 293(3): L525 - L534. [Abstract] [Full Text] [PDF]

				S. Belmadani, J. Bernal, C.-C. Wei, M. A. Pallero, L. Dell'Italia, J. E. Murphy-Ullrich, and K. H. Berecek A Thrombospondin-1 Antagonist of Transforming Growth Factor-{beta} Activation Blocks Cardiomyopathy in Rats with Diabetes and Elevated Angiotensin II Am. J. Pathol., September 1, 2007; 171(3): 777 - 789. [Abstract] [Full Text] [PDF]

				A. J. Galliher and W. P. Schiemann Src Phosphorylates Tyr284 in TGF-{beta} Type II Receptor and Regulates TGF-{beta} Stimulation of p38 MAPK during Breast Cancer Cell Proliferation and Invasion Cancer Res., April 15, 2007; 67(8): 3752 - 3758. [Abstract] [Full Text] [PDF]

				P. C. Gray, G. Shani, K. Aung, J. Kelber, and W. Vale Cripto Binds Transforming Growth Factor {beta} (TGF-{beta}) and Inhibits TGF-{beta} Signaling Mol. Cell. Biol., December 15, 2006; 26(24): 9268 - 9278. [Abstract] [Full Text] [PDF]

				S. Biswas, T. L. Criswell, S. E. Wang, and C. L. Arteaga Inhibition of Transforming Growth Factor-{beta} Signaling in Human Cancer: Targeting a Tumor Suppressor Network as a Therapeutic Strategy. Clin. Cancer Res., July 15, 2006; 12(14): 4142 - 4146. [Full Text] [PDF]

				A. Bandyopadhyay, J. K. Agyin, L. Wang, Y. Tang, X. Lei, B. M. Story, J. E. Cornell, B. H. Pollock, G. R. Mundy, and L.-Z. Sun Inhibition of Pulmonary and Skeletal Metastasis by a Transforming Growth Factor-{beta} Type I Receptor Kinase Inhibitor. Cancer Res., July 1, 2006; 66(13): 6714 - 6721. [Abstract] [Full Text] [PDF]

				Y. Kang, W. He, S. Tulley, G. P. Gupta, I. Serganova, C.-R. Chen, K. Manova-Todorova, R. Blasberg, W. L. Gerald, and J. Massague Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway PNAS, September 27, 2005; 102(39): 13909 - 13914. [Abstract] [Full Text] [PDF]

				J. Dai, J. Keller, J. Zhang, Y. Lu, Z. Yao, and E. T. Keller Bone Morphogenetic Protein-6 Promotes Osteoblastic Prostate Cancer Bone Metastases through a Dual Mechanism Cancer Res., September 15, 2005; 65(18): 8274 - 8285. [Abstract] [Full Text] [PDF]

				A. Moustakas and C.-H. Heldin Non-Smad TGF-{beta} signals J. Cell Sci., August 15, 2005; 118(16): 3573 - 3584. [Abstract] [Full Text] [PDF]